Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 1/2020

01-01-2020 | Infliximab | Original Research

Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China

Authors: Haotian Chen, Jihao Shi, Yipeng Pan, Zhou Zhang, Hao Fang, Ying Chen, Wendong Chen, Qian Cao

Published in: Advances in Therapy | Issue 1/2020

Login to get access

Abstract

Objectives

To assess the cost-effectiveness of reimbursing infliximab for moderate-to-severe Crohn’s disease (MS-CD) in China from the perspective of public insurance payers.

Methods

A decision-analytic model with a lifetime time horizon was constructed to simulate the disease progression and direct medical costs in Chinese MS-CD patients under two scenarios: reimbursing infliximab vs. not reimbursing infliximab. A cross-sectional study and literature review were conducted to estimate model variables. The constructed decision-analytic model ran the base case, one-way sensitivity, and probabilistic sensitivity analyses (PSA) to assess the cost-effectiveness of reimbursing infliximab using reimbursed medical costs.

Results

Base case analysis discounting health benefits and costs estimated that reimbursing infliximab could increase overall survival by 0.604 years, increase total quality-adjusted life years (QALY) by 0.697 QALY, reduce absolute lifetime surgery risk by 13.1%, and increase reimbursed costs by ¥29,409. The incremental cost-effectiveness ratio per gained additional QALY (ICER) based on discounted health benefits and reimbursed medical costs (3% per year) was ¥42,198. The one-way sensitivity analyses identified that the cost-effectiveness of reimbursing infliximab for MS-CD was mainly driven by the treatment efficacies of maintenance therapy, quality of life, and unit price of infliximab. PSA estimated that reimbursing infliximab was associated with a 63.8% chance to be cost-effective under the willingness-to-pay of the 2018 Chinese gross domestic product per capita (GDPPC).

Conclusion

Reimbursing infliximab for MS-CD in Chinese patients was highly attractive, costing Chinese public insurance payers less than the 2018 Chinese GDPPC to gain 1 QALY.
Literature
1.
Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380(9853):1590–605.PubMed
2.
Cohen RD. The quality of life in patients with Crohn’s disease. Aliment Pharmacol Ther. 2002;16(9):1603–9.PubMed
3.
Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn’s disease. J Clin Gastroenterol. 2005;39(5):390–5.PubMed
4.
Behzadi P, Behzadi E, Ranjbar R. The incidence and prevalence of Crohn’s disease in global scale. SOJ Immunol. 2015;3(2):1–6.
5.
Economou M, Pappas G. New global map of Crohn’s disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14(5):709–20.PubMed
6.
Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Rev Gastroenterol Hepatol. 2006;3(7):390.
7.
Irving PM, Gearry RB, Sparrow MP, Gibson PR. Appropriate use of corticosteroids in Crohn’s disease. Aliment Pharmacol Ther. 2007;26(3):313–29.PubMed
8.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.PubMed
9.
Sands BE, Blank MA, Patel K, Van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol. 2004;2(10):912–20.PubMed
10.
Tang DH, Harrington AR, Lee JK, Lin M, Armstrong EP. A systematic review of economic studies on biological agents used to treat Crohn’s disease. Inflamm Bowel Dis. 2013;19(12):2673–94.PubMed
11.
Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517.PubMed
12.
Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn’s disease. Ann Surg. 2000;231(1):38.PubMedPubMedCentral
13.
Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8(4):357–63.PubMed
14.
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.PubMed
15.
D’Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–7.PubMed
16.
Suzuki Y, Motoya S, Takazoe M, et al. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn’s disease: a multicentre, double-blind, randomized, parallel-group Phase II study. J Crohns Colitis. 2013;7(3):239–47.PubMed
17.
Tromm A, Bunganič I, Tomsová E, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology. 2011;140(2):425–34.PubMed
18.
Yokoyama T, Ohta A, Motoya S, et al. Efficacy and safety of oral budesonide in patients with active Crohn’s disease in Japan: a multicenter, double-blind, randomized, parallel-group phase 3 study. Inflamm Intest Dis. 2017;2(3):154–62.PubMedPubMedCentral
19.
Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn’s disease after surgery: a systematic review and network meta-analysis. Gastroenterology. 2015;148(1):64–76.PubMed
20.
Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.PubMed
21.
Du XY. Clinical study of surgical treatment for cute abdomen caused by crohn’s disease. China Mod Med. 2011;18(31):36.
22.
Duan M, Li Y, Guo Z, et al. Clinical analysis of acute severe gastrointestinal bleeding in Crohn’s disease. Chin J Gastroenterol. 2018;23(1):38–41.
23.
Feng SC, Cao ZY, Jiang T, et al. Diagnosis and treatment of 29 cases of Crohn’s disease. J Nantong Univ (Medical Sciences). 2010;30(3):187–9.
24.
Lu JY, Ling GL, Qiu HZ, et al. Surgical treatment of the complications of Crohn’s disease. Chin J Mod Oper Surg. 2014;18(01):9–11.
25.
Luan Y, Zong GQ, Chen J, et al. Surgical treatment of Crohn’s disease: an analysis of 19 cases. World Chin J Gastroenterol. 2011;19(17):1851–4.
26.
Niu LY, Tian LJ, Yang JY, et al. Clinical analysis of surgical treatment of Crohn’s disease. Chin Remedies Clin. 2018;18(10):1774–6.
27.
Wang JH, Lin JJ. Clinical effect of surgical treatment of structuring Crohn’s disease. Chin J Dig Surg. 2016;15(12):1160–4.
28.
Xie Y, Dou XT, Yao YL, et al. Experience of urinary tract fistulas complicating Crohn’s disease. Parenter Enter Nutr. 2014;21(3):163–6.
29.
Xue F, Ling F, Feng N, et al. Surgical treatment of Crohn’s disease with free perforation: an analysis of 10 cases. Chin J Inflamm Bowel Dis. 2017;1(3):180–2.
30.
Yang B, Ji JB, Lv CY. Surgical treatment of 10 cases for Crohn’s disease. World Health Dig Med Period. 2011;08(29):10–1.
31.
Zhang GN, Huang SR, Qin QZ, et al. Application of laparoscope in Crohn’s disease diagnosis and treatment. J Minim Invasive Med. 2011;06(4):307–8.
32.
Zhang HB, Han Y, Ling MB, et al. Laparoscopic surgery for the treatment of Crohn’s disease. J Surg Concepts Pract. 2012;17(4):370–3.
33.
Zheng JT, Zhang CY, Li LQ, et al. Risk factors associated with postoperative complications after reoperation for recurrent Crohn disease. Chin J Gastrointestinal Surg. 2011;14(3):181–4.
34.
Zhong MN, Wu B, Niu BZ, et al. Analysis of surgery-related complications and risk factors of ileocolic Crohn’s disease. Chin J Dig Surg. 2016;15(12):1165–9.
35.
Zhong ZQ, Song MM, Bai RX. Analysis of clinical manifestations and emergency operations of Crohn disease: a report for 26 cases. Chin J Postgrad Med. 2009;32(26):20–3.
36.
Zhou W, Xiang JJ, Liu W. Surgical treatment of ileosigmoid fistulas in Crohn’s disease. Chin J Gen Surg. 2016;31(4):322–4.
37.
Zhu XB, Shi S, Ji GH, et al. Clinical analyses for patients of acute abdomen caused by Crohn’s disease. Med J Present Clin. 2015;28(5):1600–1.
38.
Gong J, Wei Y, Gu L, et al. Outcome of surgery for coloduodenal fistula in Crohn’s disease. J Gastrointest Surg. 2016;20(5):976–84.PubMed
39.
Huang CQ, Wang DX. Analysis of risk factors associated with poor prognosis and prognosis of colonic and non-colon-type Crohn’s disease. J Gastroenterol Hepatol (Chinese). 2018;27(05):45–9.
40.
Lei XM, Lu L. Clinical characteristics and prognosis analysis of severe Crohn’s disease. J Chengde Med Coll (Chinese). 2017;04:35–7.
41.
Wang M, Ding YB, Xiao WM, et al. Efficacy and safety analysis of long-term application of azathioprine in Crohn’s disease. J Gastroenterol Hepatol (Chinese). 2011;20(7):647–9.
42.
Wang QZ, Wang SJ. Clinical characteristics and survival status of patients with inflammatory bowel disease. China Minkang Medicine (Chinese). 2017;(3):1–3.
43.
Aniwan S, Harmsen WS, Tremaine WJ, et al. Overall and cause-specific mortality of inflammatory bowel disease in olmsted county, minnesota, from 1970 through 2016. Mayo Clin Proc. 2018;93(10):1415–22.PubMed
44.
Hovde Ø, Kempski-Monstad I, Småstuen MC, et al. Mortality and causes of death in Crohn’s disease: results from 20 years of follow-up in the IBSEN study. Gut. 2014;63(5):771.PubMed
45.
Caini S, Bagnoli S, Palli D, et al. Total and cancer mortality in a cohort of ulcerative colitis and Crohn’s disease patients: the florence inflammatory bowel disease study, 1978–2010. Dig Liver Dis. 2016;48(10):1162–7.PubMed
46.
Camus M, Seksik P, Bourrier A, et al. Long-term outcome of patients with Crohn’s disease who respond to azathioprine. Clin Gastroenterol Hepatol. 2013;11(4):389–94.PubMed
47.
D’haens G, Reinisch W, Colombel JF, et al. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn’s disease treated with infliximab [Remicade®] or conventional therapy. J Crohn’s Colitis. 2017;11(6):680–9.
48.
Eshuis EJ, Peters CP, van Bodegraven AA, et al. Ten years of infliximab for Crohn’s disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis. 2013;19(8):1622–30.PubMed
49.
Greener T, Shapiro R, Klang E, et al. Clinical outcomes of surgery versus endoscopic balloon dilation for structuring Crohn’s disease. Dis Colon Rectum. 2015;58(12):1151–7.PubMed
50.
Manninen P, Karvonen AL, Huhtala H, et al. Mortality in ulcerative colitis and Crohn’s disease. A population-based study in Finland. J Crohn’s Colitis. 2012;6(5):524–8.
51.
Rönnblom A, Thörn M, Holmström T, Karlbom U, Tanghöj H, Sjöberg D. Clinical course of Crohn’s disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005–2009. Scand J Gastroenterol. 2017;52(1):81–6.PubMed
52.
Selinger CP, Andrews J, Dent OF, et al. Cause-specific mortality and 30-year relative survival of Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2013;19(9):1880–8.PubMed
53.
Wang G, Ren J, Song LIU, et al. Clinical characteristics of non-perianal fistulating Crohn’s disease in China: a single-center experience of 184 cases. Chin Med J. 2012;125(14):2405–10.PubMed
54.
Yasukawa S, Matsui T, Yano Y, et al. Crohn’s disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan. J Gastroenterol. 2019;54(1):42–52.PubMed
55.
Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Jensen GV, Torp-Pedersen C, Nielsen OH, Gislason GH, Hansen PR. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death—a Danish nationwide cohort study. PLoS One. 2013;8(2):e56944.PubMedPubMedCentral
56.
57.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–2.PubMed
58.
Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess (Winchester, England). 2003;7(27):3–9.
59.
60.
Gao X, Yang RP, Chen MH, et al. Risk factors for surgery and postoperative recurrence: analysis of a south China cohort with Crohn’s disease. Scand J Gastroenterol. 2012;47(10):1181–91.PubMed
61.
Chow DK, Sung JJ, Tsoi KK, et al. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study. Aliment Pharmacol Ther. 2009;29(8):843–54.PubMed
62.
Leong RW, Lee YT, Ching JY, Sung JJ. Quality of life in Chinese patients with inflammatory bowel disease: validation of the Chinese translation of the Inflammatory Bowel Disease Questionnaire. Aliment Pharmacol Ther. 2003;17(5):711–8.PubMed
63.
Guo Z, Wu R, Zhu W, et al. Effect of exclusive enteral nutrition on health-related quality of life for adults with active Crohn’s disease. Nutr Clin Pract. 2013;28(4):499–505.PubMed
64.
Li J, Liu Q, Chen Y, et al. Treatment patterns, complications, and direct medical costs associated with ankylosing spondylitis in Chinese urban patients: a retrospective claims dataset analysis. J Med Econ. 2017;20(1):91–7.PubMed
65.
Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99(1):91.PubMed
66.
Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess (Winchester, England). 2011;15(6):1.PubMedCentral
67.
Royall RM. The effect of sample size on the meaning of significance tests. Am Statistician. 1986;40(4):313–5.
68.
Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. Criteria for distinguishing effectiveness from efficacy trials in systematic reviews. Rockville: Agency for Healthcare Research and Quality (US); 2006 (Technical Reviews, No. 12.).
Metadata
Title
Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China
Authors
Haotian Chen
Jihao Shi
Yipeng Pan
Zhou Zhang
Hao Fang
Ying Chen
Wendong Chen
Qian Cao
Publication date
01-01-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 1/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-01150-x

Other articles of this Issue 1/2020

Advances in Therapy 1/2020 Go to the issue

Original Research

Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland

Original Research

Prospective, Multicenter, Cross-Sectional Survey on Dry Eye Disease in Japan

Study Protocol

Application of Dried Human Amnion Graft to Improve Post-Prostatectomy Incontinence and Potency: A Randomized Exploration Study Protocol

Original Research

Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study

Review

Pathophysiology and Therapeutic Perspectives of Oxidative Stress and Neurodegenerative Diseases: A Narrative Review

Original Research

A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits